{
  "slug": "curium",
  "name": "Curium",
  "description": "A global leader in nuclear medicine, specializing in the development, manufacturing, and distribution of radiopharmaceutical products for diagnostic imaging and therapeutic applications in oncology, cardiology, and neurology.",
  "url": "https://optimly.ai/brand/curium",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/https://www.curium.ai/",
  "baiScore": 41,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Healthcare",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-07-26T00:03:14.414Z",
  "verifiedVitals": {
    "website": "https://www.curiumpharma.com",
    "founded": "2017",
    "headquarters": "Paris, France",
    "pricing_model": "Contract-based, volume-based, and premium pricing for specialized therapies.",
    "core_products": "Diagnostic radiotracers (e.g., for PET/SPECT imaging), therapeutic radiopharmaceuticals (e.g., for targeted cancer therapy).",
    "key_differentiator": "Extensive global infrastructure for manufacturing and distributing short-lived radioisotopes, a broad portfolio across diagnostic and therapeutic applications, and strong regulatory compliance expertise.",
    "target_markets": "Hospitals, imaging centers, oncology clinics, cardiology departments, neurology specialists globally.",
    "employee_count": "1001-5000",
    "funding_stage": "Private Equity Backed",
    "subcategory": "Radiopharmaceuticals"
  },
  "intentTags": {
    "problemIntents": [
      "Traditional Diagnostic Imaging: Utilizing conventional imaging techniques such as CT, MRI, and X-ray without radiopharmaceuticals, which may offer anatomical detail but often lack the specific functio",
      "Contract Research Organizations (CROs): Outsourcing radiopharmaceutical development, clinical trials, and regulatory affairs to specialized CROs instead of maintaining extensive in-house capabilities."
    ],
    "solutionIntents": [
      "Curium nuclear medicine",
      "radiopharmaceuticals for cancer",
      "Curium investor relations",
      "Curium side effects",
      "Curium diagnostics",
      "Non-Radiological Biomarkers: Employing alternative diagnostic methods like blood tests, genetic markers, or tissue biopsies for disease detection, monitoring, and therapy selection, which do not invol"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1785296605643
}